

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Applicant : Andrianov *et al.*
Serial No. : 10/715,788
Filed : November 18, 2003
Title : POLYPHOSPHAZENE IMMUNOSTIMULANTS
Examiner : Gyan Chandra
Art Unit : 1646
Attorney Docket No. : 533860-99

COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, VA 22313-1450

January 12, 2005

SIR:

Pursuant to 37 C.F.R. §1.56(a), Applicant(s) hereby cite(s) the enclosed document(s) listed on the attached copy of Form PTO-1449 which are believed to be material to the patentability of the above-identified application.

This Information Disclosure Statement is filed in accordance with the paragraph of 37 CFR §1.97 indicated below:

____ §1.97(b) This Information Disclosure Statement is filed:

- (1) Within three months of the filing date of a national application other than a continued prosecution application under §1.53(d); OR
- (2) Within three months of the date of entry of the national stage as set forth in §1.491 in an international application; OR
- (3) Before the mailing of a first Office action on the merits; OR
- (4) Before the mailing of a first Office action after the filing of a request for continued examination under §1.114.

01/24/2005 RFEKADUI 00000008 10715788

01 FC:1806

180.00 0P

No fee or statement is required.

X §1.97(c) This Information Disclosure Statement is filed after the period specified in paragraph (b) above, but before the mailing date of either:

- (1) A final action under 37 CFR §1.113; OR
 - (2) A notice of allowance under 37 CFR §1.311; OR
 - (3) An action that otherwise closes prosecution;
- AND

is accompanied by either: (check one)

 The statement as specified in 37 CFR §1.97(e) set out below;
OR

X The fee of \$180.00 under 37 CFR §1.17(p).

 §1.97(d) This Information Disclosure Statement is filed after the mailing date of either:

- (1) A final action under 37 CFR §1.113; OR
- (2) A notice of allowance under 37 CFR §1.311; OR
- (3) An action that otherwise closes prosecution;

BUT filed on or before payment of the Issue Fee; AND

is accompanied by:

- (1) The statement as specified in 37 CFR §1.97(e) as set forth below; AND

 The fee of \$180.00 under 37 CFR §1.17(p).

 §1.97(e) The undersigned Attorney hereby states that:

 each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement;

or

 no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned Attorney after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

The Commissioner is authorized to charge payment of any fees associated with this communication or to credit any overpayment to Deposit Account No. 03-0678.

Serial No: 10/715,788
Filed: November 18, 2003

CERTIFICATE OF MAILING

Deposit Date: January 12, 2005


I hereby certify that this paper and the attachments hereto are being deposited today with the U.S. Postal Service with sufficient postage as First Class Mail to Addressee, under 37 CFR 1.8, on the date indicated above addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Raymond E. Stauffer, Esq.

1/12/05
Date

Respectfully submitted,


Raymond E. Stauffer, Esq.
Reg. No. 47,109
CARELLA, BYRNE, BAIN, GILFILLAN,
CECCHI, STEWART & OLSTEIN
5 Becker Farm Road
Roseland, NJ 07068
Tel. No.: (973) 994-1700
Fax No.: (973) 994-1744

#244147 v1 - IDS

Form PTO-1449

Atty. Docket:

533860-99

Serial No.:

10/715,788

INFORMATION DISCLOSURE STATEMENT

Applicant: Andrianov, et al.

Filing Date: November 18, 2003

Group: 1646

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Sub-Class	Filing Date
	A1	5,500,161	3/19/96	Andrianov, et al.	264	8	9/21/93
	B1	5,399,485	3/21/95	Regnery, et al.	435	7.32	1/17/92
	C1	5,644,047	7/1/97	Anderson, et al.	536	23.7	5/18/94
	D1	5,693,776	12/2/97	Anderson, et al.	536	23.1	6/7/95
	E1	5,736,347	4/7/98	Anderson, et al.	435	7.32	9/16/94
	F1	4,880,622	11/14/89	Allcock, et al.	424	78	5/20/86
	G1	5,529,777	6/25/96	Andrianov, et al.	424	184.1	11/4/93
	H1	5,891,444	4/6/99	Jenkins, et al.	424	208.1	6/7/95
	I1	5,807,757	9/15/98	Andrianov, et al.	436	535	7/2/96
	J1	5,707,597	1/13/98	Andrianov, et al.	423	265	11/13/96
	K1	5,814,704	9/29/98	Andrianov, et al.	525	209	3/4/97
	L1	5,842,471	12/1/98	Andrianov, et al.	528	398	5/14/97
	M1	5,869,016	2/9/99	Andrianov, et al.	423	300	6/18/97
	N1	5,760,271	6/2/98	Andrianov, et al.	558	93	8/18/97
	O1	6,207,171	3/27/01	Payne, et al.	424	280	3/25/99
	P1	6,261,573	7/17/01	Loebelenz, et al.	424	278.1	10/25/99

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Country	Class	Sub-Class	Translation
	Q1						<input type="checkbox"/> Yes <input type="checkbox"/> No
	R1						<input type="checkbox"/> Yes <input type="checkbox"/> No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

S1	Aderem, et al., Toll-like receptors in the induction of the innate immune response, Nature, Vol. 406, P. 783, August 2000.
T1	Kataoka, et al., Activation of Macrophages by Linear (1→3)-β-D-Glucans, Journal of Biological Chemistry, 2002, Vol. 277, No. 39, Pages 36825-36826.
U1	Chen, et al., Targeting epidermal Langerhans cells by epidermal powder immunization, Cell Research (2002); 12 (2):97-104.
V1	Payne, et al., (1995) Chapter 20, 473-493 in Vaccine Design: The Subunit and Adjuvant Approach; ed. Powell and Newman; Plenum Press, NY, 1995.

	W1	Lu, et al., Utility of SHIV for Testing HIV-1 Vaccine Candidates in Macaques; J Acquir Immune Defic. Syndr. (1996), 12, 99-106.
	X1	Payne, et al, Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine, Vaccine (1998), Vol. 16, No. 1, pp. 92-98.
	Y1	Karem, et al., Bartonella henselae, B. quintana, and B. bacilliformis: historical pathogens of emerging significance, Microbes and Infection (2000) 2, 1193-1205.
	Z1	O'Reilly, et al., Passive Antibody to Bartonella henselae Protects against Clinical Disease following Homologous Challenge but Does Not Prevent Bacteremia in Cats, Infection and Immunity (2001), 69, 3, 1880-1882.
Examiner:		Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.		

533860-99
#244091 v1